LTR Pharma (ASX:LTP) Operating Income : A$ Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Operating Income?

LTR Pharma's Operating Income for the six months ended in Jun. 2023 was A$-1.44 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. LTR Pharma's Operating Income for the six months ended in Jun. 2023 was A$-1.44 Mil. LTR Pharma's Revenue for the six months ended in Jun. 2023 was A$0.00 Mil. Therefore, LTR Pharma's Operating Margin % for the quarter that ended in Jun. 2023 was %.

LTR Pharma's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LTR Pharma's annualized ROC % for the quarter that ended in Jun. 2023 was -439.14%. LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -6,613.64%.

LTR Pharma Operating Income Historical Data

The historical data trend for LTR Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Operating Income Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Operating Income

-0.03

-1.03

-1.44

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Operating Income	-0.03	-1.03	-1.44

LTR Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was A$ Mil.

LTR Pharma (ASX:LTP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LTR Pharma's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-1.436 * ( 1 - 0% )	/	( (0.3	+	0.354)	/ 2 )
=	-1.436	/	0.327
=	-439.14 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.245	-	0.466	-	( 1.911	-	max(0, 0.476	-	1.955	+	1.911	))
=	0.3

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.51	-	0.011	-	( 7.145	-	max(0, 0.021	-	7.21	+	7.145	))
=	0.354

Note: The Operating Income data used here is one times the annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.455	/	( ( (0 + max(-0.432, 0))	+	(0 + max(0.044, 0)) )	/	2 )
=	-1.455	/	( ( 0	+	0.044 )	/	2 )
=	-1.455	/	0.022
=	-6,613.64 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.044)	-	(0.466	+	0	+	0.01)
=	-0.432

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.065)	-	(0.011	+	0	+	0.01)
=	0.044

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

LTR Pharma's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.436	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

LTR Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines